Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.48 |
| ▸ | PDE4A | P27815 | 9/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4364149 | 0.76 | PDE4B (0.53) | PDE4BPDE4APDE4DPDE4CKMT2A | |
| SCHEMBL4365529 | 0.75 | PDE4B (0.56) | PDE4BPDE4APDE4DPDE4CKMT2A | |
| SCHEMBL788982 | 0.74 | ALDH1A1 (0.46) | KMT2ADRD2DRD3 | |
| SCHEMBL4375614 | 0.74 | PDE4B (0.55) | PDE4BPDE4APDE4DPDE4CKMT2A | |
| SCHEMBL4369467 | 0.72 | PDE4B (0.53) | PDE4BPDE4APDE4DPDE4CKMT2A | |
| SCHEMBL31357933 | 0.68 | HTR1A (0.30) | — | |
| SCHEMBL29104329 | 0.68 | DRD2 (0.43) | KMT2ADRD2DRD1DRD4DRD5 | |
| SCHEMBL3680200 | 0.66 | ALPL (0.52) | PDE4BKMT2A | |
| SCHEMBL4363589 | 0.66 | PDE4B (0.46) | PDE4BPDE4APDE4DPDE4CKMT2A | |
| SCHEMBL29150475 | 0.65 | DRD2 (0.36) | PDE4BPDE4APDE4DPDE4CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008006052-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4D 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.